Abbvie (ABBV) PTAB Decision Incrementally Positive, But Does Not Change Cautious Thesis - BMO

November 7, 2016 1:40 PM EST
Get Alerts ABBV Hot Sheet
Price: $61.99 --0%

Rating Summary:
    10 Buy, 12 Hold, 1 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 10 | Down: 6 | New: 3
Trade ABBV Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

BMO Capital analyst Alex Arfaei weighed in on Abbvie (NYSE: ABBV), calling the PTAB denying institution of the Coherus (NASDAQ; CHRS) IPR of Humira formulation patent is incrementally positive for ABBV, but it does not change their cautious thesis

Arfaei commented, "We still see a long litigation path and increased uncertainty ahead. We remain cautious on Humira’s growth prospects because of increased competition from biosimilars and JAK-1s, particularly Lilly’s Baricitinib. Just as AbbVie's $3Bn Hep-C guidance by 2020 now seems unrealistic, we believe that in 2017-2018 so will the >$18Bn Humira guidance. Thus, we remain significantly below ($15Bn)."

The firm maintained a Market Perform rating and price target of $63.00

For an analyst ratings summary and ratings history on Abbvie click here. For more ratings news on Abbvie click here.

Shares of Abbvie closed at $56.04 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Trader Talk

Related Entities

BMO Capital

Add Your Comment